RU2009101972A - Комбинации, содержащие стауроспорины - Google Patents
Комбинации, содержащие стауроспорины Download PDFInfo
- Publication number
- RU2009101972A RU2009101972A RU2009101972/15A RU2009101972A RU2009101972A RU 2009101972 A RU2009101972 A RU 2009101972A RU 2009101972/15 A RU2009101972/15 A RU 2009101972/15A RU 2009101972 A RU2009101972 A RU 2009101972A RU 2009101972 A RU2009101972 A RU 2009101972A
- Authority
- RU
- Russia
- Prior art keywords
- group
- mcl
- ness
- hydrogen
- carboxy
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims abstract 16
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims abstract 16
- -1 carboxy carboxy, carboxy, carboxy, carboxy, carboxy, carboxy, carboxy, carboxy carbamoyl Chemical group 0.000 claims abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 239000001257 hydrogen Substances 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 12
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims abstract 10
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims abstract 10
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims abstract 10
- 239000003112 inhibitor Substances 0.000 claims abstract 10
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 9
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract 9
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 125000003277 amino group Chemical group 0.000 claims abstract 7
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical group C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims abstract 7
- 150000002431 hydrogen Chemical class 0.000 claims abstract 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract 5
- 206010025323 Lymphomas Diseases 0.000 claims abstract 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
- 208000032839 leukemia Diseases 0.000 claims abstract 5
- 241000124008 Mammalia Species 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 3
- 150000002367 halogens Chemical class 0.000 claims abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims abstract 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002411 imatinib Drugs 0.000 claims abstract 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000651 prodrug Substances 0.000 claims abstract 2
- 229940002612 prodrug Drugs 0.000 claims abstract 2
- 125000002252 acyl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 238000010276 construction Methods 0.000 claims 3
- IIQIEMHSDLLZQA-QZPVEUDVSA-N n-((9s,10r,11r,13r)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1h,9h-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)benzodiazonin-11-yl)-n-methyl-benzamide Chemical group CN([C@H]1[C@@]([C@]2(C)O[C@H]1N1C3=CC=CC=C3C3=C4C(=O)NCC4=C4C5=CC=CC=C5N2C4=C31)(C)OC)C(=O)C1=CC=CC=C1 IIQIEMHSDLLZQA-QZPVEUDVSA-N 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005257 alkyl acyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0612542.1A GB0612542D0 (en) | 2006-06-23 | 2006-06-23 | Combinations comprising staurosporines |
| GB0612542.1 | 2006-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009101972A true RU2009101972A (ru) | 2010-07-27 |
Family
ID=36803826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009101972/15A RU2009101972A (ru) | 2006-06-23 | 2007-06-22 | Комбинации, содержащие стауроспорины |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100184820A1 (https=) |
| EP (1) | EP2037933A2 (https=) |
| JP (1) | JP2009541240A (https=) |
| KR (1) | KR20090033874A (https=) |
| CN (1) | CN101505760A (https=) |
| AU (1) | AU2007263278A1 (https=) |
| BR (1) | BRPI0713730A2 (https=) |
| CA (1) | CA2655724A1 (https=) |
| GB (1) | GB0612542D0 (https=) |
| MX (1) | MX2008016488A (https=) |
| RU (1) | RU2009101972A (https=) |
| WO (1) | WO2007147613A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009143578A1 (en) * | 2008-05-28 | 2009-12-03 | The Council Of The Queensland Institute Of Medical Research | Cancer drug target and methods of diagnosis and therapy |
| CN102101866A (zh) * | 2010-11-04 | 2011-06-22 | 中国海洋大学 | 十字孢碱卤代衍生物及其制备方法和应用 |
| FI20115640A0 (fi) * | 2011-06-22 | 2011-06-22 | Turun Yliopisto | Yhdistelmähoito |
| FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
| DK2872631T3 (en) * | 2012-07-13 | 2017-06-12 | Turun Yliopisto | COMBINATION THERAPY |
| CN110526903B (zh) * | 2016-06-01 | 2021-12-10 | 中国海洋大学 | 双吲哚马来酰亚胺衍生物及其制备方法和用途 |
| CN106083830B (zh) * | 2016-06-01 | 2019-07-12 | 中国海洋大学 | 双吲哚马来酰亚胺衍生物及其制备方法和用途 |
| SG10201607303YA (en) | 2016-09-01 | 2018-04-27 | Agency Science Tech & Res | Antisense oligonucleotides to induce exon skipping |
| WO2019000224A1 (zh) * | 2017-06-27 | 2019-01-03 | 中国海洋大学 | 双吲哚马来酰亚胺衍生物及其制备方法和用途 |
| CN107569491A (zh) * | 2017-08-30 | 2018-01-12 | 杭州科兴生物化工有限公司 | 一种星孢菌素类化合物的应用 |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| CN114437109B (zh) * | 2022-03-08 | 2023-09-29 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种十字孢碱卤代衍生物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001992A (en) * | 1999-01-07 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
| ES2269793T3 (es) * | 2001-10-30 | 2007-04-01 | Novartis Ag | Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3. |
| BRPI0413439A (pt) * | 2003-08-08 | 2006-10-17 | Novartis Ag | combinações compreendendo estaurosporinas |
-
2006
- 2006-06-23 GB GBGB0612542.1A patent/GB0612542D0/en not_active Ceased
-
2007
- 2007-06-22 AU AU2007263278A patent/AU2007263278A1/en not_active Abandoned
- 2007-06-22 US US12/305,390 patent/US20100184820A1/en not_active Abandoned
- 2007-06-22 WO PCT/EP2007/005517 patent/WO2007147613A2/en not_active Ceased
- 2007-06-22 JP JP2009515774A patent/JP2009541240A/ja active Pending
- 2007-06-22 RU RU2009101972/15A patent/RU2009101972A/ru unknown
- 2007-06-22 CN CNA200780030602XA patent/CN101505760A/zh active Pending
- 2007-06-22 KR KR1020097001396A patent/KR20090033874A/ko not_active Withdrawn
- 2007-06-22 CA CA002655724A patent/CA2655724A1/en not_active Abandoned
- 2007-06-22 BR BRPI0713730-3A patent/BRPI0713730A2/pt not_active IP Right Cessation
- 2007-06-22 MX MX2008016488A patent/MX2008016488A/es not_active Application Discontinuation
- 2007-06-22 EP EP07764787A patent/EP2037933A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007147613A3 (en) | 2008-07-03 |
| MX2008016488A (es) | 2009-01-22 |
| CA2655724A1 (en) | 2007-12-27 |
| JP2009541240A (ja) | 2009-11-26 |
| US20100184820A1 (en) | 2010-07-22 |
| EP2037933A2 (en) | 2009-03-25 |
| CN101505760A (zh) | 2009-08-12 |
| WO2007147613A2 (en) | 2007-12-27 |
| BRPI0713730A2 (pt) | 2012-10-30 |
| GB0612542D0 (en) | 2006-08-02 |
| AU2007263278A1 (en) | 2007-12-27 |
| KR20090033874A (ko) | 2009-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009101972A (ru) | Комбинации, содержащие стауроспорины | |
| JP2009541240A5 (https=) | ||
| JP6401773B2 (ja) | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 | |
| US10316049B2 (en) | Tank-binding kinase inhibitor compounds | |
| ES2718900T3 (es) | Inhibidores de EZH2 humana y métodos de uso de los mismos | |
| JP6527534B2 (ja) | ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 | |
| AU2020214802A1 (en) | Compounds and uses thereof | |
| CA2462657A1 (en) | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity | |
| JP5852678B2 (ja) | 抗腫瘍剤の効果増強剤 | |
| US10407423B2 (en) | Compounds as inhibitors of DNA methyltransferases | |
| CY1121699T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| CY1111069T1 (el) | Παραγωγα διυδροπυραζολοπυριμιδινονης | |
| CN105263941A (zh) | 2-{[(2r,3s,5r)-5-(4-氨基-2-氧代-2h-嘧啶-1-基)-3-羟基-四氢-呋喃-2-基甲氧基]-苯氧基-磷酰基氨基}-丙酸烷基酯类、hcv rna-聚合酶ns5b的核苷抑制剂、其制备方法及用途 | |
| JP2008528467A5 (https=) | ||
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| RU2011129383A (ru) | Производное амина, обладающее антагостической активностью в отношении рецептора npy y5 | |
| JP2009536620A5 (https=) | ||
| NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
| RU2013126094A (ru) | Замещённые пиразолопиримидины как активаторы глюкоцереброзидазы | |
| NO20060670L (no) | N3-substituerte imidazopyridin C-kit inhibitorer | |
| NO20071234L (no) | Forbindelser som potensierer glutamatreseptor og anvendelse derav innen medisin | |
| AU2018361828A1 (en) | Antibacterial compounds | |
| WO2012013557A1 (en) | Isoxazolo-quinazolines as modulators of protein kinase activity | |
| KR20210061356A (ko) | 혈액암 치료를 위한 조합요법 | |
| Liu et al. | Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1 H-indazol-6-yl) pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer |